[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2008004734A - Composicion rica en leucina. - Google Patents

Composicion rica en leucina.

Info

Publication number
MX2008004734A
MX2008004734A MX2008004734A MX2008004734A MX2008004734A MX 2008004734 A MX2008004734 A MX 2008004734A MX 2008004734 A MX2008004734 A MX 2008004734A MX 2008004734 A MX2008004734 A MX 2008004734A MX 2008004734 A MX2008004734 A MX 2008004734A
Authority
MX
Mexico
Prior art keywords
fraction
composition
leucine rich
provides
rich composition
Prior art date
Application number
MX2008004734A
Other languages
English (en)
Inventor
Johannes Adrianus Cornelis Peters
Robert Johan Joseph Hageman
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of MX2008004734A publication Critical patent/MX2008004734A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invención se refiere al uso de una composición que comprende materia proteinácea, que proporciona al menos 24.0% del valor energético de la composición (en %) y al menos 12% en peso basado en la materia proteinácea leucina en la elaboración de un medicamento para el tratamiento de resistencia a la insulina y a una composición adecuada para la administración a un mamífero que comprende una fracción de proteína, una fracción de carbohidrato y una fracción de lípido, en donde la fracción de proteína proporciona al menos 24.0% (en %), el carbohidrato proporciona hasta 46 %, la fracción de lípido proporciona hasta 30 % y en donde al menos 12 % en peso, basado en la materia proteinácea, de leucina.
MX2008004734A 2005-10-12 2006-10-11 Composicion rica en leucina. MX2008004734A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077339 2005-10-12
EP20050077579 EP1774973A1 (en) 2005-10-12 2005-11-11 Leucine rich composition
PCT/NL2006/000515 WO2007043870A1 (en) 2005-10-12 2006-10-11 Leucine rich composition

Publications (1)

Publication Number Publication Date
MX2008004734A true MX2008004734A (es) 2008-10-23

Family

ID=36228553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008004734A MX2008004734A (es) 2005-10-12 2006-10-11 Composicion rica en leucina.

Country Status (12)

Country Link
US (1) US20080275120A1 (es)
EP (2) EP1774973A1 (es)
JP (2) JP2009511576A (es)
CN (1) CN101325951A (es)
AU (1) AU2006300046A1 (es)
BR (1) BRPI0617358A2 (es)
CA (1) CA2625819A1 (es)
IL (1) IL190671A0 (es)
MX (1) MX2008004734A (es)
RU (1) RU2428977C2 (es)
WO (1) WO2007043870A1 (es)
ZA (1) ZA200803856B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
WO2009157759A1 (en) 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
ITMI20081405A1 (it) * 2008-07-29 2010-01-30 Velleja Res Srl Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia
WO2011078654A1 (en) * 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2011119023A1 (en) * 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
TR201808471T4 (tr) 2010-07-05 2018-07-23 Beth Israel Deaconess Medical Ct Inc Sn-2-monoaçilgliseroller ve lipid malabsorpsiyonu.
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
EP2705844B1 (en) 2011-04-13 2019-05-22 Ajinomoto Co., Inc. Nutritional composition
CA2832150A1 (en) * 2011-04-18 2012-10-26 Nestec S.A. Nutritional compositions having alpha-hica and alpha-ketoglutarate
US9713598B2 (en) * 2013-03-14 2017-07-25 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
AU2013392167B2 (en) 2013-06-10 2017-04-27 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
FR3015860B1 (fr) * 2013-12-30 2019-08-16 Pronokal Health Group, Sociedad Limitada Composition alimentaire de regime pour diminuer l'inflammation de bas grade a court et long terme comprenant de l'acide docosahexaenoique
CN105769844B (zh) * 2016-05-25 2019-01-11 天津嘉氏堂医美科技有限公司 一种含精氨酸的组合物及制剂
EP3510999A4 (en) 2016-09-09 2020-03-11 Ajinomoto Co., Inc. PREVENTION OR REMEDY COMPOSITION AGAINST DEMENTIA OR DEPRESSION
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
CN113519850A (zh) * 2020-04-13 2021-10-22 内蒙古蒙牛乳业（集团）股份有限公司 肿瘤全营养乳剂、其制备方法和用途
CN113582871B (zh) * 2021-09-29 2022-01-04 北京天赋神奇科技有限公司 一种含镁水溶性欧米伽3脂肪酸

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
US6890571B2 (en) * 2002-05-14 2005-05-10 National Starch And Chemical Investment Holding Corporation Slowly digestible starch product
EP1513419A2 (en) * 2002-06-19 2005-03-16 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7037522B2 (en) * 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
US7288570B2 (en) * 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US8697679B2 (en) * 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
BRPI0412182A (pt) * 2003-06-30 2006-08-22 Nestec Sa composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina
JP2008506772A (ja) * 2004-07-19 2008-03-06 エヌ．ブイ．・ヌートリシア ケトン体の調節のために、アスパラギン酸塩およびビタミンｂ１２またはビオチンを使用するための製剤
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition

Also Published As

Publication number Publication date
JP2009511576A (ja) 2009-03-19
BRPI0617358A2 (pt) 2011-07-26
CN101325951A (zh) 2008-12-17
CA2625819A1 (en) 2007-04-19
AU2006300046A2 (en) 2008-05-08
ZA200803856B (en) 2009-04-29
EP1774973A1 (en) 2007-04-18
WO2007043870A1 (en) 2007-04-19
JP2013139470A (ja) 2013-07-18
IL190671A0 (en) 2008-11-03
EP1945199A1 (en) 2008-07-23
AU2006300046A1 (en) 2007-04-19
RU2008118341A (ru) 2009-11-20
RU2428977C2 (ru) 2011-09-20
US20080275120A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
MX2008004734A (es) Composicion rica en leucina.
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
EP2570431A3 (en) Compositions and methods of using proislet peptides and analogs thereof
NO20075009L (no) Ernaeringstilsetning for HIV-pasienter
TW200605870A (en) Topical methadone compositions and methods for using the same
BRPI0515316A (pt) compostos de imidazoquinolina
WO2004084950A3 (en) Cell targeting methods and compositions
EP1907014A4 (en) CHONDROGENIC COMPOSITIONS AND METHODS OF USE
MY138708A (en) Biaryloxymethylarenecarboxylic acids
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EP1749517B8 (en) Stable pharmaceutical composition comprising linezolid form IV
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2009068708A8 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
HK1085927A1 (en) The use of lupin conglutin for the preparation of a medicament, food supplements or foods for the treatment of type ii diabetes
CY1115938T1 (el) Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)
WO2007134118A3 (en) Protein based composition and methods of using same
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
AU2003202550A1 (en) Pharmaceutical formulations with modified release
WO2009085198A3 (en) Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2005077400A8 (en) Cysteine rich peptides for improving thiol homeostasis
ATE510009T1 (de) Förderung der peroxisomalenkatalasefunktion in zellen
WO2007045982A3 (en) Use of collagen in combination with oxygen- and ozonereleasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions

Legal Events

Date Code Title Description
FG Grant or registration